Leritrelvir: Difference between revisions

X.l.xiong (talk | contribs)

← Previous edit

Monkbot (talk | contribs)

m →top: Monkbot/task 21: Replace page(s) with article-number;

}}

}}

'''Leritrelvir''' ('''RAY1216''') is an [[antiviral]] drug which acts as a [[3C-like protease]] inhibitor. It was developed and approved<ref>{{cite journal | doi = 10.1038/s41392-024-01770-y | title = Targeted drug approvals in 2023: Breakthroughs by the FDA and NMPA | date = 2024 | journal = Signal Transduction and Targeted Therapy | volume = 9 | issue = 1 | page = 46 | pmid = 38378623 | pmc = 10879080 | vauthors = Zheng L, Wang W, Sun Q }}</ref> in China for treatment of [[COVID-19]].<ref>{{cite journal | vauthors = Chen X, Huang X, Ma Q, Kuzmic P, Zhou B, Zhang S, Chen J, Xu J, Liu B, Jiang H, Zhang W, Yang C, Wu S, Huang J, Li H, Long C, Zhao X, Xu H, Sheng Y, Guo Y, Niu C, Xue L, Xu Y, Liu J, Zhang T, Spencer J, Zhu Z, Deng W, Chen X, Chen SH, Zhong N, Xiong X, Yang Z | title = Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir | journal = Nature Microbiology | volume = 9 | issue = 4 | pages = 1075-1088 | date = April 2024 | doi = 10.1038/s41564-024-01618-9 | pmid = 38553607 | pmc = 10994847 }}</ref><ref>{{cite journal | vauthors = Janin YL | title = On the origins of SARS-CoV-2 main protease inhibitors | journal = RSC Medicinal Chemistry | volume = 15 | issue = 1 | pages = 81–118 | date = January 2024 | doi = 10.1039/d3md00493g | pmid = 38283212 | pmc = 10809347 }}</ref><ref>{{cite journal | vauthors = Chan CC, Guo Q, Chan JF, Tang K, Cai JP, Chik KK, Huang Y, Dai M, Qin B, Ong CP, Chu AW, Chan WM, Ip JD, Wen L, Tsang JO, Wang TY, Xie Y, Qin Z, Cao J, Ye ZW, Chu H, To KK, Ge XY, Ni T, Jin DY, Cui S, Yuen KY, Yuan S | title = Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics | journal = Acta Pharmaceutica Sinica. B | volume = 14 | issue = 9 | pages = 4028–4044 | date = September 2024 | doi = 10.1016/j.apsb.2024年05月02日6 | pmid = 39309487 | pmc = 11413674 }}</ref><ref>{{cite journal | vauthors = Cao Q, Ding Y, Xu Y, Li M, Zheng R, Cao Z, Wang W, Bi Y, Ning G, Xu Y, Zhao R | title = Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116) | journal = Frontiers of Medicine | volume = 17 | issue = 6 | pages = 1068–1079 | date = December 2023 | doi = 10.1007/s11684-023-1037-3 | pmid = 38165534 }}</ref><ref>{{cite journal | vauthors = Zheng B, Zhao Q, Yang W, Feng P, Xin C, Ying Y, Yang B, Han B, Zhu J, Zhang M, Li G | title = Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis | journal = International Journal of Antimicrobial Agents | volume = 63 | issue = 3 | (削除) pages (削除ここまで) = 107096 | date = March 2024 | doi = 10.1016/j.ijantimicag.2024.107096 | pmid = 38244811 | doi-access = free }}</ref>

'''Leritrelvir''' ('''RAY1216''') is an [[antiviral]] drug which acts as a [[3C-like protease]] inhibitor. It was developed and approved<ref>{{cite journal | doi = 10.1038/s41392-024-01770-y | title = Targeted drug approvals in 2023: Breakthroughs by the FDA and NMPA | date = 2024 | journal = Signal Transduction and Targeted Therapy | volume = 9 | issue = 1 | page = 46 | pmid = 38378623 | pmc = 10879080 | vauthors = Zheng L, Wang W, Sun Q }}</ref> in China for treatment of [[COVID-19]].<ref>{{cite journal | vauthors = Chen X, Huang X, Ma Q, Kuzmic P, Zhou B, Zhang S, Chen J, Xu J, Liu B, Jiang H, Zhang W, Yang C, Wu S, Huang J, Li H, Long C, Zhao X, Xu H, Sheng Y, Guo Y, Niu C, Xue L, Xu Y, Liu J, Zhang T, Spencer J, Zhu Z, Deng W, Chen X, Chen SH, Zhong N, Xiong X, Yang Z | title = Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir | journal = Nature Microbiology | volume = 9 | issue = 4 | pages = 1075-1088 | date = April 2024 | doi = 10.1038/s41564-024-01618-9 | pmid = 38553607 | pmc = 10994847 }}</ref><ref>{{cite journal | vauthors = Janin YL | title = On the origins of SARS-CoV-2 main protease inhibitors | journal = RSC Medicinal Chemistry | volume = 15 | issue = 1 | pages = 81–118 | date = January 2024 | doi = 10.1039/d3md00493g | pmid = 38283212 | pmc = 10809347 }}</ref><ref>{{cite journal | vauthors = Chan CC, Guo Q, Chan JF, Tang K, Cai JP, Chik KK, Huang Y, Dai M, Qin B, Ong CP, Chu AW, Chan WM, Ip JD, Wen L, Tsang JO, Wang TY, Xie Y, Qin Z, Cao J, Ye ZW, Chu H, To KK, Ge XY, Ni T, Jin DY, Cui S, Yuen KY, Yuan S | title = Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics | journal = Acta Pharmaceutica Sinica. B | volume = 14 | issue = 9 | pages = 4028–4044 | date = September 2024 | doi = 10.1016/j.apsb.2024年05月02日6 | pmid = 39309487 | pmc = 11413674 }}</ref><ref>{{cite journal | vauthors = Cao Q, Ding Y, Xu Y, Li M, Zheng R, Cao Z, Wang W, Bi Y, Ning G, Xu Y, Zhao R | title = Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116) | journal = Frontiers of Medicine | volume = 17 | issue = 6 | pages = 1068–1079 | date = December 2023 | doi = 10.1007/s11684-023-1037-3 | pmid = 38165534 }}</ref><ref>{{cite journal | vauthors = Zheng B, Zhao Q, Yang W, Feng P, Xin C, Ying Y, Yang B, Han B, Zhu J, Zhang M, Li G | title = Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis | journal = International Journal of Antimicrobial Agents | volume = 63 | issue = 3 | (追記) article-number (追記ここまで) = 107096 | date = March 2024 | doi = 10.1016/j.ijantimicag.2024.107096 | pmid = 38244811 | doi-access = free }}</ref>

== References ==

== References ==